Takeda Says Will Be Working With FDA Towards Voluntary Withdrawal Of EXKIVITY (mobocertinib) In US; Says Phase 3 EXCLAIM-2 Confirmatory Trial Did Not Meet Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical Company Limited (TAK) announced its intention to voluntarily withdraw its drug EXKIVITY (mobocertinib) in the US after the Phase 3 EXCLAIM-2 confirmatory trial did not meet its primary endpoint. The company also plans to initiate similar withdrawals globally where the drug is approved. Takeda will continue to assess the impact of the withdrawal and update its full-year, consolidated forecast for the fiscal year ending March 31, 2024.
October 02, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Takeda's decision to withdraw EXKIVITY could potentially impact its revenues and stock price. The company's future financial forecasts may also be affected.
The withdrawal of a drug from the market, especially after failing to meet trial endpoints, can have significant financial implications for a pharmaceutical company. This could lead to a decrease in expected revenues and potentially affect the company's stock price. The company's future financial forecasts may also need to be revised.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100